https://www.businesswire.com/news/home/20250207924380/en/AceLink-Therapeutics-Presents-Interim-Results-from-a-Phase-2-Trial-of-the-GCS-Inhibitor-AL01211-in-Treatment-Nave-Classic-Male-Fabry-Disease-Patients-at-the-WORLD-Symposium-2025
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in...
AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data fro...
https://www.boletalent.com/
Acelink 领炬科技 | 海外高层次人才引进官方委托机构
Acelink是一家以深度服务高层次人才及 “解决关键挑战”为基石的创新创业落地咨询机构，由周知博士创办，致力于帮助海外高层次人才实现更高的自我价值，并抓住中国变革中的机遇。以人才的实际发展需求为核心，...